BRAF inhibitors, such as vemurafenib, encorafenib, or dabrafenib, have shown benefit in clinical trials in patients with thyroid cancer carrying the BRAFV600E mutation 93. The gene discussed is BRAF; the disease is thyroid gland carcinoma.